Viasat Misses Q4 Earnings Estimates on Flat Y/Y Revenues
Viasat, Inc. VSAT reported mixed fourth-quarter fiscal 2025 results, wherein the adjusted earnings missed the Zacks Consensus Estimate while the top line beat the same.
The company's top line remained relatively flat year over year, reflecting declines in fixed broadband and product revenues within Communication Services. This was offset by strong growth in Aviation and Information Security, Space and Mission systems and tactical networking in the Defense and Advanced Technologies segment.
Viasat incurred a net loss of $246.1 million, or a loss of $1.89 per share, compared with a net loss of $100.3 million, or a loss of 80 cents per share, in the prior-year quarter.Excluding non-recurring items, Viasat reported a non-GAAP net loss of $3.01 million, or a loss of 2 cents per share, compared with a net loss of $30.5 million, or a loss of 24 cents per share, in the prior-year period. The bottom line missed the Zacks Consensus Estimate by 5 cents.For fiscal 2025, the company reported a net loss of $575 million, or a loss of $4.48 per share, compared with a net loss of $1.06 billion, or a loss of $9.12 per share, in fiscal 2024. Non-GAAP net income was $21.1 million, or 16 cents per share, compared with a net income of $148.5 million, or $1.25 per share, in 2024.
Viasat Inc. price-consensus-eps-surprise-chart | Viasat Inc. Quote
Revenues remained almost flat at $1.15 billion. The figure surpassed the consensus estimate by $13 million. Product revenues were $349.7 million, up from $337.9 million in the year-ago quarter. Net sales from Service decreased to $797.4 million from $812 million a year ago. For fiscal 2025, the company reported record revenues of $4.5 billion, up from $4.3 billion reported in 2024.Revenues from the Communication Services segment were $825 million, down 4% from $859.9 million in the year-ago quarter, owing to declines in fixed services and other, and maritime service revenues, partially offset by continued growth in government satcom and aviation services. However, the segment's adjusted EBITDA improved to $306.2 million from $300.2 million.Revenues from the Defense and Advanced Technologies (DAT) segment were $322 million, up 11% year over year. The uptick was primarily driven by solid traction across information security and cyber defense, space and mission systems and tactical networking products. Adjusted EBITDA improved to $68.6 million from $57.5 million in the year-ago quarter, backed by the strong revenue growth across the segment.
In the March quarter, Viasat reported an operating loss of $153.8 million against an operating income of $0.3 million in the prior-year quarter. Adjusted EBITDA was $374.8 million, up from $357.7 million in the year-ago quarter.
During the fourth quarter of fiscal 2025, Viasat generated an operating cash flow of $298 million compared with $232 million in the prior-year period, reflecting improved operating performance and a decline in working capital largely from increases in accounts payable and other accrued liabilities. As of March 31, 2025, the company has $1.61 billion in cash and cash equivalents, with a net debt of $5.6 billion compared to respective figures of $1.9 billion and $5.6 billion in the prior-year quarter.
For fiscal 2026, management expects low single-digit year-over-year revenue growth and flattish year-over-year adjusted EBITDA. Viasat anticipates Communication Services segment's flat revenue performance to be driven by low double-digit growth in aviation services, partially offset by a lower rate of declines in fixed services and other. DAT revenue growth is anticipated to be in the mid-teens, primarily driven by strong double-digit growth in both information security and cyber defense and space and mission systems. Capital expenditure is forecasted to be approximately $1.3 billion (includes approximately $450 million for Inmarsat-related capital expenditures).
Viasat currently carries a Zacks Rank #3 (Hold).Here are some better-ranked stocks that investors may consider.Juniper Networks, Inc. JNPR sports a Zacks Rank of 1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks hereIn the last reported quarter, it delivered an earnings surprise of 4.88%. Juniper is leveraging the 400-gig cycle to capture hyperscale switching opportunities within the data center. The company is set to capitalize on the increasing demand for data center virtualization, cloud computing and mobile traffic packet/optical convergence. Juniper also introduced new features within its AI-driven enterprise portfolio, enabling customers to simplify the rollout of their campus wired and wireless networks while providing greater insight to network operators.InterDigital IDCC carries a Zacks Rank #2 (Buy) at present. In the trailing four quarters, InterDigital delivered an earnings surprise of 160.15%. The company is a pioneer in advanced mobile technologies that enable wireless communications and capabilities.InterDigital designs and develops a wide range of advanced technology solutions used in digital cellular, wireless 3G, 4G and IEEE 802-related products and networks.Arista Networks, Inc. ANET, carrying a Zacks Rank of 2 at present, supplies products to a prestigious set of customers, including Fortune 500 global companies in markets such as cloud titans, enterprises, financials and specialty cloud service providers.Arista delivered a trailing four-quarter average earnings surprise of 11.82% and has a long-term growth expectation of 14.81%. Arista currently serves five verticals, namely cloud titans (customers that deploy more than one million servers), cloud specialty providers, service providers, financial services and the rest of the enterprise
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Juniper Networks, Inc. (JNPR) : Free Stock Analysis Report
InterDigital, Inc. (IDCC) : Free Stock Analysis Report
Viasat Inc. (VSAT) : Free Stock Analysis Report
Arista Networks, Inc. (ANET) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Intercontinental Exchange Reports 13% Rise in May Average Daily Volume
Intercontinental Exchange, Inc. (NYSE:ICE) is among the . The company recently reported a strong 13% year-over-year rise in its average daily volume for May. Open interest also hit a record high, increasing 8% to 104.6 million contracts. A team of mortgage originators using a closing solution platform for quick and accurate mortgage processing. Notable gains came from the Energy and Sugar markets, with daily volumes up 10% and 8%, respectively. The Financials segment stood out with a 21% jump in average daily volume, highlighting ICE's broad-based momentum across its trading platforms. Intercontinental Exchange, Inc. (NYSE:ICE) is a strong dividend payer, having raised its payouts for 12 consecutive years. In the past five years, the company has grown its dividend by over 10%. It pays a quarterly dividend of $0.45 per share and has a dividend yield of 1.08%, as of June 14. Intercontinental Exchange, Inc. (NYSE:ICE) develops and runs digital platforms that link people to opportunities. It offers financial technology and data services across key asset classes, helping clients improve transparency and streamline essential workflows. While we acknowledge the potential of ICE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Sign in to access your portfolio
Business Wire
25 minutes ago
- Business Wire
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its entry into a clinical master supply agreement with Roche for future studies investigating the combination of MAIA's telomere-targeting agent ateganosine (THIO), sequenced with Roche's checkpoint inhibitor (CPI), atezolizumab (Tecentriq®), for the treatment of multiple hard-to-treat cancers. 'In preclinical studies, ateganosine was found to be highly synergistic and effective in combination with Roche's anti-PD-L1 agent atezolizumab,' said MAIA Chairman and CEO Vlad Vitoc, M.D. 'We are pleased to partner with world-renowned Roche and we look forward to further strengthening our mission to find safe and effective cancer treatments.' About Ateganosine Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2'-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activate both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group. Forward-Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as 'may,' 'might,' 'will,' 'should,' 'could,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'project,' 'intend,' 'future,' 'potential,' or 'continue,' and other similar expressions are intended to identify forward-looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, 'MAIA,' 'Company,' 'we,' 'our,' and 'us' refers to MAIA Biotechnology, Inc. and its subsidiaries.
Yahoo
26 minutes ago
- Yahoo
AgroFresh Expands Global Post-Harvest Solutions Portfolio with NatuWrap® in Exclusive Distribution Agreement with Nabaco®
PHILADELPHIA and SAN MARCOS, Texas, June 18, 2025 /CNW/ -- AgroFresh Solutions, Inc., a global leader in post-harvest quality and freshness solutions, and Nabaco®, Inc., a platform science company specializing in eco-friendly solutions for farmers, produce packers, and beyond, including its NatuWrap® fruit protection technologies, today announced an exclusive distribution agreement. AgroFresh will serve as the global commercial partner for NatuWrap, bringing the solution to fresh produce packers and processors worldwide. The agreement adds to AgroFresh's growing portfolio of innovative freshness technologies that meet the produce industry's desire for more natural solutions. "At AgroFresh, we're focused on delivering impactful solutions that address the evolving needs of our customers," said AgroFresh Chief Executive Officer (CEO) Clint Lewis. "Our company aim is to continuously identify unique, novel technologies, developed internally or through our partners, that address the needs of our customers. NatuWrap, developed by Nabaco, Inc., is a tangible example of this innovation commitment, helping to sustainably protect fruit quality throughout the produce supply chain." NatuWrap is a food-grade solution made from USDA National Organic Program (NOP) listed ingredients and is Organic Materials Review Institute (OMRI) certified. It forms a gentle, protective barrier that helps reduce scuffing, bruising and other damage during handling and storage. This delivers meaningful quality benefits across a variety of crops, including apples, pears, citrus, and cherries. As the U.S. cherry packing season begins, NatuWrap has been shown to reduce pitting and help maintain greener, fresher-looking stems, resulting in higher-quality fruit at retail. "NatuWrap represents a new standard in fruit protection – novel, effective and easy to integrate into existing operations," said Nabaco CEO Jamie Strachan. "AgroFresh's strong global reach and deep experience in post-harvest solutions makes them the ideal partner to scale the benefits of our technology to the widest possible range of fruit and vegetable packers and processors." This agreement is the latest in a series of strategic partnerships and new innovations from AgroFresh, underscoring the company's commitment to transforming the fresh produce industry with smart, sustainable post-harvest technologies. About AgroFreshAgroFresh is the global leader in post-harvest quality and freshness solutions that enhance quality and extend shelf-life of fresh produce, reducing food loss and waste. AgroFresh has been innovating for more than 40 years to address fresh produce supply chain challenges from all angles with a full suite of integrated storage, packing line and digital solutions. As the pioneer of SmartFresh™, the world's first introduction to 1-MCP technology used to slow ripening, and Uvasys™, the world's first laminated SO2 generating sheets that prevent fungal decay in produce, AgroFresh empowers growers, packers and retailers to succeed in delivering fresh, quality and sustainable produce from harvest to home. To learn more about AgroFresh, visit About NabacoNabaco, Inc. is a Texas-based materials science company revolutionizing industries with its patented, eco-friendly solutions for farmers, produce packers, and beyond. Our flagship post-harvest product, NatuWrap®, is a food-grade, temporary barrier designed to protect fruits and vegetables during processing and storage. By helping packers improve quality and yield, NatuWrap® supports better returns to the farm and the planet. View original content to download multimedia: SOURCE AgroFresh Solutions, Inc. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
